TYSABRI (natalizumab) is indicated as monotherapy (i.e. single disease-modifying agent) for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. TYSABRI is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.

Consult the product monograph at www.biogen.ca/products/TYSABRI_PM_EN for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

TECFIDERA (dimethyl fumarate) is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the progression of disability.

Consult the product monograph at www.biogen.ca/products/TECFIDERA_PM_EN for contraindications, warnings, precautions, adverse reactions, drug interactions and dosing. The Product Monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

PLEGRIDY (peginterferon beta-1a) is indicated for the treatment of relapsing remitting multiple sclerosis (RRMS) for adult patients

• to reduce the frequency of clinical exacerbations
• to slow the progression of disability

Consult the product monograph at www.biogen.ca/products/PLEGRIDY_PM_EN for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

AVONEX PS/AVONEX PEN (interferon beta-1a) is indicated for:

• Treatment of relapsing forms of multiple sclerosis (MS)
  • To slow the progression of disability
  • To decrease the frequency of clinical exacerbations
  • To reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans
• A subgroup of relapsing MS includes secondary progressive MS (SPMS) patients who are still experiencing relapses, also known as relapsing progressive MS (RPMS)
• Treatment of people who have experienced a single demyelinating event, accompanied by abnormal MRI scans, with lesions typical of MS:
  • To delay the onset of clinically definite MS (as determined by a second demyelinating event);
  • To decrease the number and volume of active brain lesions and overall disease burden (as identified by MRI scans). Before initiating treatment with AVONEX PS/AVONEX PEN, alternate diagnoses should first be excluded.

Consult the product monograph at www.biogen.ca/products/AVONEX_PM_EN for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available by contacting Biogen Canada Inc. at 1-866-359-2502.

^PrFAMPYRA^TM (fampridine) extended release tablets are indicated for the symptomatic improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS 3.5–7).

Not indicated in patients <18 years of age.

Please consult the Product Monograph for important information relating to warnings and precautions, adverse reactions, drug interactions, missed dose and dosing information that has not been discussed in this piece. 

The Product Monograph can also be obtained by contacting Biogen Canada Inc. at: 1-866-359-2502

Biogen-105098